FC
CLDI icon

Finepoint Capital’s Calidi Biotherapeutics CLDI Stock Holding History

Finepoint Capital’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$177 Hold
65
– – ﹤0.01% 9
2026
Q1 		$249 Hold
65
– – ﹤0.01% 9
2025
Q4 		$1.22K Hold
65
– – ﹤0.01% 9
2025
Q3 		$1.58K Hold
65
– – ﹤0.01% 9
2025
Q2 		$2.88K Hold
65
– – ﹤0.01% 10
2025
Q1 		$7.08K Hold
65
– – ﹤0.01% 25
2024
Q4 		$14.4K Hold
65
– – ﹤0.01% 26
2024
Q3 		$14.2K Hold
65
– – ﹤0.01% 25
2024
Q2 		$25K Hold
65
– – 0.01% 25
2024
Q1 		$70.6K Hold
65
– – 0.02% 20
2023
Q4 		$189K Hold
65
– – 0.06% 18
2023
Q3 		$416K Buy
+65
New +$1.05M 0.21% 17

Other funds holding CLDI

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
IAA
Independent Advisor Alliance Charlotte, North Carolina $4.27B AUM 45.92% 1-Year Est. Return
RCI
RS Crum Inc Newport Beach, California $533M AUM 20.75% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BAM
Belpointe Asset Management Reno, Nevada $3.06B AUM 23.82% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Finepoint Capital's CLDI Position: Q2 2026 in Review

Finepoint Capital held its Calidi Biotherapeutics (CLDI) position steady in Q2 2026 at 65 shares worth $177. The position accounts for ﹤0.01% of the portfolio, ranked #9.

Finepoint Capital first reported a position in CLDI in Q3 2023 and has held it in 12 quarters since. The position peaked at $416K in Q3 2023. 22 funds tracked by Wall St. Rank hold CLDI as of Q2 2026.

  • Finepoint Capital held 65 shares of Calidi Biotherapeutics worth $177 as of Q2 2026.
  • Finepoint Capital left its Calidi Biotherapeutics share count unchanged in Q2 2026.
  • Calidi Biotherapeutics made up ﹤0.01% of Finepoint Capital's portfolio in Q2 2026, its #9 holding.
  • Finepoint Capital first reported a position in Calidi Biotherapeutics in Q3 2023 and has held it in 12 quarters since.
  • Finepoint Capital's Calidi Biotherapeutics position peaked at $416K in Q3 2023.
  • 22 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q2 2026.

Based on Finepoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.